Unmet Need in DLBCL
Significant unmet need persists in 1L DLBCL
~4 out of 10 patients with DLBCL are at risk of progression after 1L treatment with R-CHOP 2,3
- The majority of relapses after 1L treatment occur within the first 2 years4
- The prognosis of patients with DLBCL diminishes with each subsequent line of therapy5
- Subsequent treatments are generally associated with additional toxicity and cost2,6,7
New treatments are needed to improve outcomes in 1L DLBCL patients8
- Approximately 30,000 new cases of DLBCL are diagnosed per year in the United States and this number is expected to increase on a yearly basis9
- Patients classified as IPI ≥ 2 are ~2-4 times more likely to relapse within 2 years compared with IPI 0-1 patients10
Because the risk of progression is so great for patients with DLBCL, the 1L treatment decision is particularly vital8,11
Since the adoption of R-CHOP in 2006, there has been limited therapeutic progress in 1L DLBCL12
~20 clinical trials evaluating other regimens have been conducted, none of which led to FDA approval12
POLIVY + R-CHP represents an important milestone in the treatment of 1L DLBCL1
References:
- POLIVY, Israeli MoH approved prescribing information,Aug 2022
- Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858. doi:10.1056/NEJMra2027612.
- Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620.
- Maurer MJ, Habermann TM, Shi Q, et al. Utility of 2-year PFS24 to predict subsequent outcomes for patients with DLBCL enrolled on randomized clinical trials: findings from a surrogate endpoint in aggressive lymphoma (SEAL) analysis of individual patient data from 5853 patients. Blood. 2018; 128:3027.
- Morrison VA, Shou Y, Bell JA, et al. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol. 2019;15(9):1021-1034.
- Purdum A, Tieu R, Reddy SR, Broder MS. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229-1236. doi:10.1634/ theoncologist.2018-0490.
- Wang R, Roth J, Ng C, Hossain F, Li J, Masaquel A. Cost of disease progression after frontline (1L) R-CHOP in diffuse large B-cell lymphoma (DLBCL). Presented at: the American Society of Hematology Annual Meeting in Atlanta, GA; December 12, 2021. Poster presentation; Abstract 3002.
- Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020; 135(23): 2041-2048.
- Kanas G, Ge Wenzhen, Quek R, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma. 2021;63()1:54-63.
- Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021; 11(1):9.
- Shi X, Liu X, Li X, et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and international prognostic index: a multicenter retrospective study. Front Oncol. 2021; 11:754964.
- Iacoboni G, Zucca E, Ghielmini M, Stathis A. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol. 2018;29(5):1120-1129. doi:10.1093/annonc/mdy113.
Contact The Hematology Team
Roche Pharmaceuticals (Israel) Ltd.
🏢 6 Hacharash St. Hod Hasharon
📞09-9737777
📧 israel.Hematology@roche.com